Clinical Trials
29 trialsNCT03919240 2026-06-04
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting
NCT03960840 2026-06-04
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT03114865 2026-06-03
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT04195347 2026-06-03
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05848687 2026-06-03
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT05579132 2026-06-01
MK-1045-002
MSD R&D (China) Co., Ltd.
Phase 1/2 Recruiting
NCT03504644 2026-05-29
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group
Phase 1/2 Active not recruiting
NCT04521231 2026-05-28
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Active not recruiting
NCT05442515 2026-05-28
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03573700 2026-05-20
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT07155226 2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2 Recruiting
NCT07387926 2026-05-19
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT06308588 2026-05-15
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04067336 2026-05-13
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Active not recruiting
NCT07584889 2026-05-13
CAR-p40-T
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT07109219 2026-05-11
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT06481735 2026-05-08
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT03984968 2026-05-07
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting
NCT04726241 2026-05-05
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
Phase 1/2 Recruiting
NCT03670966 2026-05-04
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06364423 2026-05-04
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT02392572 2026-04-14
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04811560 2026-04-14
cAMeLot-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05322850 2026-04-13
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Phase 1/2 Suspended
NCT00576979 2026-03-24
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1/2 Completed
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting